Last reviewed · How we verify
ALLO-ASCs
At a glance
| Generic name | ALLO-ASCs |
|---|---|
| Also known as | Allogeneic adipose-derived stem cells |
| Sponsor | A.A. Partners, LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Allogeneic ADSCs and Platelet-Poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds (ADSCs-BWs) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALLO-ASCs CI brief — competitive landscape report
- ALLO-ASCs updates RSS · CI watch RSS
- A.A. Partners, LLC portfolio CI